|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||94.39 / 127.00|
Cramer shares his views on how tired he is of hearing about Kool-Aid, and wonders if Apple could be valued as a consumer-products company one day.
Doug Kass shares his thoughts on Procter & Gamble, and wonders if the market is about to slip its moorings.
Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug.
Celgene Corporation (NASDAQ: CELG) today announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with...
Some tried-and-true indicators show what's really going on with the market.
Celgene's rebound off the January lows could soon develop into a fresh move higher.
Jim Cramer's bullish on ZELTIQ Aesthetics, Chesapeake Energy, Priceline Group and more.
Jim Cramer says it's a sea change: It's not just about economic growth, it's about global growth without inflation.
The company had been free falling after CEO Erez Vigodman stepped down last week.
Jim Cramer compares Allergan's growth to other pharma stocks.
Celgene Corporation (NASDAQ:CELG) plans to present at an upcoming investor conference where Celgene management will provide an overview of the Company.
Generics for drugs facing shortages or having few manufacturers is bill's focus.
Carrot-stick 'arrangement' with biotech is a fair tradeoff but will produce winners and losers.
Biotech and drugs stocks are soaring Tuesday after President Donald Trump met with CEOs of the biotech and pharma industries Tuesday.
Doug Kass shares his thoughts on Starbucks, and discusses what, if anything, Dow 20,000 means.
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted...
Celgene also acquired privately held biotech firm Delinia for an initial payment of $300 million and contingent, or future, payments of $475 million.
The yield on the 10-year Treasury bond walks a fine line between pleasure and pain.
Celgene Corporation (NASDAQ:CELG) reported operating results for the fourth quarter and full-year of 2016.
Celgene Corporation (NASDAQ: CELG) and Delinia, Inc. ("Delinia"), a privately held biotechnology company developing novel therapeutics for autoimmune diseases, today announced that they have entered into an agreement for...
Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.
There are several reasons why Celgene should buy Biogen.
At a time when healthcare investors seem especially primed for big, transformative biotech M&A, a deal in which Celgene acquires Biogen would be smart, profitable, opportunistic and certainly attention grabbing.
CEOs of troubled companies tend to launch public tirades against the 'evil' shorts. The rants are often a smokescreen meant to divert investors' attention from problems.